

26 September 2024

NOTICE REQUIRED UNDER ASX LISTING RULE 3.13.1

INOVIQ Limited (ASX:IIQ) (**INOVIQ** or the **Company**) advises that the Annual General Meeting (AGM) is scheduled for 28 November 2024. The closing date for the receipt of nominations from persons wishing to be considered for election as a director of the Company is 4 October 2024. Any nominations must be received in writing no later than 5.00pm (AEDT) on 4 October 2024 at the Company's registered office or via email to medwards@inoviq.com.

Shareholders will be advised of further details regarding the AGM in a separate Notice of Meeting which will be provided in due course.

Authorised for release by the Company Secretary, Mark Edwards.

- ENDS -

Dr Leearne Hinch
Chief Executive Officer
E lhinch@inoviq.com
M +61 400 414 416

David Williams
Chairman
E dwilliams@kidder.com.au
M +61 414 383 593

ABOUT INOVIQ LTD

INOVIQ Ltd (ASX:IIQ) is a biotechnology company developing next-generation diagnostics and therapeutics for cancer. INOVIQ has commercialised its fast, efficient and scalable EXO-NET exosome isolation technology for biomarker discovery and diagnostics development, and the hTERT test as an adjunct test for bladder cancer. The company is advancing clinical-stage diagnostics for detection and monitoring of ovarian and breast cancers, and early-stage exosome therapeutics for solid tumours. For more information on INOVIQ, visit www.inoviq.com